Login
Novavax NASDAQ: NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
| Name | Novavax |
| Ticker | NVAX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Clinical trial work |
|
Price
52W Low/High |
202.09
17.14 / 319.93 |
| Momentum | Neutral |
| Market cap | 13 B |
| 1Y Total Return |
1,016.52%
Strong |
| 1Y Volatility |
130.31%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
Details
| Ticker | NVAX |
| Name | Novavax |
| ISIN | US6700024010 |
| CUSIP | 670002401 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Clinical trial work |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 4/15/21
| Close Price | 202.09 |
| 52W Low/High | 17.14 / 319.93 |
| Market cap | 13 B |
| 1Y Total Return |
1,016.52%
Strong |
| 1Y Volatility |
130.31%
High Risk |
| Beta | 0.45 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -87.9% |
| Cash from Op. / Cur. Liabilities | -0.07 |
| Diluted Earnings / Share | -7.27 |
| ROE | - |
| ROIC | -192.4% |
| Price / Revenue | 24.5 |
| Price / Book | 18.5 |
| Price / CF | -273.4 |
| Current Ratio | 2.2 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.75 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
476
|
19
|
34
|
31
|
15
|
36
|
|
| Gross Profit |
476
|
19
|
34
|
31
|
15
|
36
|
|
| R&D |
747
|
114
|
174
|
168
|
238
|
163
|
|
| EBITDA |
-152
|
-113
|
-163
|
-160
|
-258
|
-151
|
|
| Operating Income |
-417
|
-121
|
-174
|
-172
|
-269
|
-157
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
58
|
24
|
18
|
15
|
14
|
13
|
|
| EPS exc. Extra |
-7.27
|
-5.51
|
-9.99
|
-12.56
|
-20.60
|
-12.00
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
1,582
|
173
|
208
|
302
|
394
|
386
|
|
| Cash, Eq & Invt ShortTerm |
806
|
82
|
104
|
186
|
270
|
268
|
|
| Total Current Assets |
1,248
|
97
|
119
|
203
|
288
|
287
|
|
| Total Non-Current Assets |
334
|
76
|
89
|
99
|
106
|
99
|
|
| Intangibles |
141
|
57
|
59
|
61
|
61
|
64
|
|
| Total Liabilities |
955
|
359
|
376
|
404
|
400
|
93
|
|
| Total Current Liabilities |
580
|
26
|
46
|
74
|
66
|
76
|
|
| Long Term Debt |
376
|
333
|
330
|
331
|
333
|
17
|
|
| Shareholder equity |
627
|
-186
|
-168
|
-102
|
-6
|
293
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-43
|
-137
|
-185
|
-144
|
-259
|
-126
|
|
| Depreciation |
251
|
6
|
8
|
10
|
9
|
6
|
|
| Cash from Investing |
-378
|
38
|
29
|
36
|
28
|
-21
|
|
| Capex |
55
|
16
|
1
|
4
|
18
|
18
|
|
| Cash from Financing |
985
|
98
|
103
|
65
|
280
|
208
|
|
| Stock Issued |
920
|
98
|
103
|
65
|
4
|
209
|
|
| Debt (LT) Issued |
-96
|
0
|
0
|
0
|
325
|
-1
|
|
| Free Cash Flow |
1
|
-132
|
-164
|
-120
|
-234
|
-121
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
2.2
|
3.8
|
2.6
|
2.8
|
4.3
|
3.8
|
|
| Financial Leverage D/E |
0.75
|
-
|
-
|
-
|
-
|
0.00
|
|
| Return on Capital Avg |
-192.4%
|
-163.7%
|
-196.9%
|
-140.2%
|
-163.0%
|
-80.7%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available